Glioblastoma multiforme is the most common and deadliest of the glial tumors because it is hard to cure with a very high possibility of recurring. Diffuse intrinsic pontine glioma (DIPG) is a sub-kind of glioblastoma that mainly affects children. It has a 5-year survival rate less than 1%.

According to the ABTA, there are nearly 700,000 people in the United States living with a primary brain and central nervous system tumor. Of these, 14.9 percent are glioblastomas. There is an estimated of 12,390 new cases predicted in 2017.

ACT001 is a drug designed and developed by Accendatech specifically used to target brain tumor for treatment of GBM and DIPG

​

ACT001
ACT001 is an investigational product currently finished testing in phase 1 clinical studies. 

Our Science

Clinical Trial